GPGI (GPGI) Q1 2026 earnings review
CompoSecure Shines, But Husky Derails the New Platform
GPGI's first quarter as a combined platform revealed a stark divergence between its two businesses. CompoSecure delivered exceptional results, with sales accelerating 26% YoY and margins expanding to 36.5%. Conversely, the newly acquired Husky segment reversed into contraction. A sudden shock in oil and resin prices caused Husky customers to freeze orders, driving a 5% revenue decline and collapsing operating margins by 770 bps. Consequently, management was forced to severely slash the bullish FY26 guidance they issued just months ago, cutting projected EBITDA by ~$55 million. The 'diversified compounder' thesis took an immediate hit from macroeconomic reality.
🐂 Bull Case
The core card business is firing on all cylinders. Driven by the Resolute Operating System (ROS) and robust demand across banks and fintechs, CompoSecure grew EBITDA by 37% YoY.
While orders plunged in March (-16% YoY), the 12-month opportunity pipeline actually grew 4% in March and accelerated to 8% in April, indicating demand is deferred rather than destroyed.
🐻 Bear Case
The rapid deterioration of Husky's orders following a resin price spike shatters the illusion of a highly predictable, recurring revenue compounder. Operating leverage cuts both ways.
Slashing FY26 revenue guidance by roughly $180 million just one quarter after the acquisition closed raises serious questions about management's forecasting visibility and the initial deal narrative.
⚖️ Verdict: 🔴
Bearish. While CompoSecure is executing flawlessly, the massive guidance cut forced by Husky's vulnerability to commodity shocks overshadows the platform's successes. A 13.2% margin at Husky is a significant regression.
Key Themes
Husky Margin Collapse Contradicts Platform Narrative
At the time of the acquisition, management touted Husky as a stable, high-margin compounder. However, Q1 exposed severe cyclicality: Pro Forma Adjusted EBITDA margins plummeted 770 bps to 13.2%. Management attributed ~250 bps of this to under-absorbed labor and ~160 bps to growth investments, with the rest coming from negative operating leverage as over $20 million in revenue was abruptly deferred. This specific data point directly contradicts the thesis that the Resolute Operating System provides immediate margin immunity.
CompoSecure Execution Accelerating
CompoSecure continues to be the bright spot. Sales growth accelerated to 25.6% YoY (up from 17% in 24Q4), generating a record $130.4 million. The Resolute Operating System (ROS) is visibly working here: improved manufacturing yields and operational efficiencies drove a 300 bps EBITDA margin expansion to 36.5%. High-profile wins including Amex Graphite, Robinhood Platinum, and Revolut Audi F1 demonstrate excellent commercial momentum.
Slashed FY26 Guidance
The macroeconomic reality check forced a severe revision to the FY26 outlook. Last quarter, GPGI guided to ~$2.2B in sales and $635M in EBITDA at the midpoint. The new guidance dramatically lowers this to $2.02B in sales and $580M in EBITDA. This represents zero organic top-line growth for the combined entity in FY26, placing massive pressure on cost-cutting actions to deliver the projected 7% EBITDA growth.
Macro Volatility Derails Husky Orders
Husky's customers shifted into a 'wait-and-see' mode in late March due to a sudden spike in PET resin prices and ongoing tariff uncertainty. While lightweighting initiatives and rPET (recycled PET) evaluations are gaining momentum as long-term tailwinds, short-term capex decisions are being actively delayed.
Arculus Innovation and Crypto Tailwinds
CompoSecure's Arculus technology continues to gain traction as a vital growth adjacency. The security and authentication platform is securing major wins in the digital asset space, specifically powering debit/credit programs for major exchanges like Kraken, X Money, and MetaMask. This integrates high-end physical metal cards with secure digital asset custody.
Other KPIs
Current leverage sits at 3.7x following the Husky acquisition, utilizing a massive $2.17 billion in total debt. Management's primary capital allocation goal is deleveraging, maintaining a target of ~3.0x by year-end 2026. The company holds ample liquidity with $122M in cash and a $322M undrawn revolver.
Despite the earnings pressure at Husky, GPGI generated $29M in Adjusted FCF during the quarter, adjusting for heavy transaction and debt refinancing expenses ($196M paid). Capital expenditures came in at $13.2M.
Guidance
Decelerating. The midpoint of $450 million implies an approximate 9% YoY decline compared to the historical pro forma Q2 2025 result of $493.7 million. This reflects the continuation of Husky's deferred order book.
Decelerating. The midpoint of $112.5 million implies a 14% YoY decline from 2Q25's $130.2 million. Margins are expected to contract roughly 140 bps YoY to ~25.0%, burdened by Husky's under-absorption.
Reversing. Downward revision from prior guidance of $2.18B-$2.23B. The new midpoint implies 0% YoY growth. Management explicitly stated that CompoSecure is expected to grow low-double-digits (LDD), while Husky is expected to decline mid-single-digits (MSD) due to macro disruptions.
Decelerating. Revised downward from the previously guided $620-$650 million. The midpoint ($580 million) implies 7% YoY growth driven by ROS cost savings and second-half fixed cost leverage, assuming the deferred Husky orders eventually convert.
Key Questions
Visibility on Husky Deferrals
You noted over $20 million in Husky revenue shifted out of Q1 and that April pipeline conversions remained extended. What specific catalysts (e.g., oil price stabilization) do you need to see for these deferred orders to turn into actual shipments in the second half?
Husky Margin Floor
Husky's margin compressed severely to 13.2%. If the macro environment remains challenging and revenue stays depressed, what is the absolute floor for Husky's margins, and how quickly can you strip out fixed costs?
M&A Appetite
Given the immediate integration challenges and demand shock at Husky, does this alter your timeline or appetite for future acquisitions until Husky's performance stabilizes and leverage returns to your 3.0x target?